Institution
Purdue Pharma
Company•Pickering, Ontario, Canada•
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..
Topics: Buprenorphine, Chronic pain, Oxycodone, Hydrocodone, Controlled release
Papers published on a yearly basis
Papers
More filters
TL;DR: It is possible to devise calibration and validation protocols that enable the ICH guidelines to conform to the specialized requirements of the NIR method of analysis.
43 citations
TL;DR: Developments in throughput capabilities and in vivo applicability have led to a renewed interest in in vitro electrophysiological techniques that, when complimented by more traditional safety pharmacology methods, often increase the preclinical predictability of potential CNS liabilities.
43 citations
TL;DR: To identify people at greater risk of opioid overdose, efforts should focus on screening for prescribed and illicit polysubstance use, impaired cognition, and changes in life circumstances, psychosocial risks/supports, and pain control.
43 citations
TL;DR: This review gives a brief overview of the expression patterns, molecular pharmacology and physiological roles of the vanilloid receptor 1 (VR1).
Abstract: This review gives a brief overview of the expression patterns, molecular pharmacology and physiological roles of the vanilloid receptor 1 (VR1). Particular emphasis is given to the therapeutic utility of VR1 modulators. Small molecule agonists of VR1, including capsaicin and RTX, are currently utilized for a number of clinical syndromes, including intractable neuropathic pain, spinal detrusor hyperreflexia, and bladder hypersensitivity; however, antagonists of VR1 have yet to reach the clinic. While the classic VR1 antagonist, capsazepine has proven a useful tool for unraveling the molecular pharmacology of VR1, in vivo studies with this compound have had limited success due to poor pharmacokinetic properties and species selectivity issues. With the cloning of VR1 in 1997, the pharmaceutical community has been provided a molecular target for high throughput screening and small molecule lead discovery and optimization. As a result, resurgence in the interest of VR1 antagonists has given way to many new pharmacological agents that may provide better tools to probe VR1 physiology, and ultimately yield promising therapeutic agents.
42 citations
Patent•
22 Dec 2011TL;DR: In this article, a solid oral dosage form comprising an inert tamper resistant core and a coating surrounding the core, the coating comprising an active agent is described, and the core is assumed to be inert.
Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.
42 citations
Authors
Showing all 622 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Gideon Koren | 129 | 1994 | 81718 |
| Asbjørn Mohr Drewes | 67 | 656 | 17287 |
| Hilary L. Surratt | 44 | 169 | 7586 |
| Ronald M. Burch | 42 | 108 | 5897 |
| John F. W. Keana | 41 | 234 | 6349 |
| Sui Xiong Cai | 39 | 91 | 4492 |
| Howard D. Chilcoat | 39 | 91 | 8739 |
| Sidney H. Schnoll | 37 | 88 | 5336 |
| Paul Coplan | 36 | 121 | 4149 |
| Benjamin Oshlack | 32 | 95 | 3902 |
| Nabarun Dasgupta | 30 | 100 | 3366 |
| Donald J. Kyle | 29 | 150 | 2390 |
| Nancy C. Lan | 29 | 50 | 3597 |
| Christopher D. Breder | 28 | 50 | 6748 |
| Michael F. Schneider | 27 | 53 | 4862 |